



Response document for MHRA public consultation on the  
proposal to make Dovonex Psoriasis Ointment available in Pharmacies

ANNEX 1

Ref: ARM95

Your details

Name

Position (if applicable):n/a

Organisation (if applicable):n/a

Email:

1. Do you consider that Dovonex Psoriasis Ointment should be available as a Pharmacy medicine?

No

Please provide any comments or evidence to support your response:

I think that the information about possible Photosensitivity and the risks of that, are not made clear, or pointedly detailed enough; for a person to make an informed choice.

2. Do you have any specific comments on the leaflet or the label provided in the public reclassification report for Dovonex Psoriasis Ointment?

3. Yes,...neither leaflet answers the question; does this make the whole of your skin photosensitive potentially, if it affects you that way:...or just the area where the topical treatment is applied?

4. Do you have any other comments on the reclassification?

I believe it should be delayed until this essential issue is seen to.

5. The MHRA may publish consultation responses. Do you want your response to remain confidential?

Partially\*I wish my name to not be disclosed – thus I wish to remain **Anonymous**.

\*If partially, please indicate which parts you wish to remain confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete.

Responses can be continued onto a separate page if required. This form should be returned by email ([reclassification@mhra.gsi.gov.uk](mailto:reclassification@mhra.gsi.gov.uk)) to arrive by **20 April 2017**. Contributions received after that date cannot be included in the exercise.